Background. Four priority target product profiles for the development of diagnostic tests for tuberculosis were identified: 1) Rapid sputum-based (RSP), 2) non-sputum Biomarker-based (BMT), 3) triage test followed by confirmatory test (TT), and 4) drug-susceptibility testing (DST).
Globally, one third of all tuberculosis cases are not identified, in part due to patients not having access to diagnosis or diagnostics being insufficiently sensitive. In addition, low coverage of drug-susceptibility testing (DST) limits the detection of multidrug-resistant tuberculosis (MDR-tuberculosis) [1] . Targets for tuberculosis prevention care and control are to reduce tuberculosis deaths and tuberculosis incidence by 95% and 90% by 2035, respectively, and achieve universal access to drug susceptibility testing [2, 3] . The World Health Assembly recognizes that new diagnostic tools are essential to achieve these new targets [2] .
The international community has defined the details of the new diagnostic tests needed in a consultative process led by the World Health Organization (WHO) in 2014 [4] [5] [6] [7] [8] [9] [10] . The final report outlining the agreed-upon target product profiles (TPPs) is available [11] . Data on costs, cost-effectiveness, and affordability of new potential diagnostic tests for tuberculosis at a country level are essential information for the international community and test developers alike. There is little available literature assessing the costs and cost-effectiveness of new diagnostics. In fact, the literature is currently restricted to an assessment of the use of a triage test (TT) prior to testing with Xpert® MTB/RIF (Cepheid, Sunnyvale, California) (Xpert). This strategy has been found to reduce total diagnostic costs when compared with using Xpert in all people presumed to have tuberculosis [7] .
This article is one in a series of articles in this supplement that discuss the new TPPs for diagnostic tests for tuberculosis and drug-resistant (DR)-tuberculosis, as well as the needs and market potential. In this article, we assessed the total costs and affordability of using new tests as described in the TPPs to diagnose tuberculosis and DR-tuberculosis in 36 high tuberculosis burden and high MDR-tuberculosis burden countries and compared it with the costs of using conventional diagnostics.
METHODS

General Information
We assessed costs from the health system perspective, that is, costs for patients were not taken into consideration, for the year 2012. All values are in 2012 US Dollars. Only costs incurred during the diagnosis of tuberculosis and DR-tuberculosis were considered. Treatment costs were not included in the analysis because the different diagnostic strategies would not change the treatment cost per patient. We acknowledge that the new diagnostic strategies will increase the number of cases identified, and thus the number of cases under treatment will increase, raising total treatment costs. The costs to reach targets set out in the Global Plan have been assessed elsewhere [12] .
Setting
Costs were estimated for 36 individual countries that appear in one or both of the lists of 22 high tuberculosis burden countries (22 HBCs) that together account for 81% of the world's tuberculosis incidence, and the 27 MDR-tuberculosis burden countries that account for about 85% of the world's cases of MDR-tuberculosis [1] .
Novel Diagnostic Tests
Two tests focused on the detection of tuberculosis either in sputum (a sputum-microscopy replacement test -[RSP]) or on specimens other than sputum (eg, urine, blood, breath; biomarker test [BMT]). A third test aims to make a triage decision (no tuberculosis or very likely tuberculosis; TT). The fourth test focuses on DST, either performing DST [D+DST] in 2 separate steps (ie, 2 reactions), or combining detection and DR-tuberculosis diagnosis [Combined D-DST] in one step (ie, one reaction). Detailed descriptions of these tests can be found in the final meeting report and in the earlier articles in this supplement [11, 13] .
Novel Diagnostic Strategies
With the novel diagnostic strategies, each patient requires only one test. A TT is always followed by Xpert as a confirmatory test. For human immunodeficiency virus (HIV)-positive people who are presumed to have tuberculosis but have a negative detection test result with any of the tests (RSP, BMT, or TT), we allow for one confirmatory test using liquid culture. All details of types and quantities of tests required in each diagnostic strategy, and associated sources of evidence, are defined in Table 1 .
Conventional Diagnostic
Each new test was compared with the base strategy. The base strategy uses conventional diagnostic algorithms according to the WHO guidelines for all countries. It involves smear microscopy, culture examinations, Xpert, drug susceptibility tests for MDR-tuberculosis on liquid media, and X-rays (Table 1 ) [14] [15] [16] [17] . Xpert is now widely used; therefore, we assume that the number of cartridges sold in 2012 by Cepheid to each country is equal to the number of people screened using Xpert, allowing for 5% indeterminate results [18] . We assume that Xpert was the first choice for tuberculosis diagnosis among all people with signs and symptoms of tuberculosis present at health facilities. The remaining people presumed to have tuberculosis would be screened and diagnosed using smear microscopy, culture and X-rays. For HIV-positive people who are presumed to have tuberculosis but have a negative Xpert test result, we allow for one confirmatory test using liquid culture [19] .
Target Population Considered
All people who present at health facilities with signs and symptoms of tuberculosis are being tested. The size of this population is based on the number of cases notified by each country and the assumption is that there are 10 suspects per 1 smear-positive case notified in 2012 [1] . In line with the TPPs, we assume that the biomarker test reaches 20% more people in all countries, compared to the population reached by the baseline strategy, since it can be performed at lower levels of the health care setting (ie, health posts) [11] . We also assume that the triage strategy reaches 30% more people in all countries because the TT can be performed by a community health worker [11] .
Costs Estimation
Costs were estimated using an ingredients approach; this means that costs were calculated by multiplying the unit cost by the quantities of tests required per year [20] . All unit costs and sources of information are shown in Table 2 . Unit costs used for the conventional tests (eg, smear microscopy, Xpert)-including capital costs-were based on previous publications [17, [21] [22] [23] [24] (Table 2) . Unit costs of new tests, and their capital costs, were based on the final report of the TPPs [11] (Table 2) . Unit costs for all the tests include only reagents, chemicals, and consumables but exclude costs for labor, overhead, space used, and transport. It is worth noting that all unit costs for the novel diagnostic tests are the result of agreement among the experts consulted for the TPP. In addition, there was no final agreement among experts on the desired optimal unit cost of the test for detection and DST. Therefore, we assumed 3 different unit costs for the DST at US $15, US $30, and US $45 for detection and DST in 2 separate steps (D+DST) and US $5, US $10 and US $20 for detection and DST combined (D-DST). All capital costs (ie, equipment) were annualized using a standard discount rate of 3% [20] and expected years of useful life of 5 years. Additional equipment for smear microscopy, culture, and DST was estimated based on the targets of the Global Plan that aimed at 1 microscopy laboratory per 100 000 people, and 1 culture and/or DST laboratory per 5 million people [12] . This ideal number of laboratories was compared with the current capacity reported by countries [25] , and only the cost of equipment was accounted for. All new strategies as well as the conventional strategy use liquid culture as a confirmatory test, therefore all strategies account for investments in equipment for culture as needed per country. The number of G-4 module Xpert 
Affordability Analysis
Affordability was assessed by comparing the costs of the new and conventional strategies with the funds that countries are currently spending on tuberculosis. In particular, the costs of conventional diagnostics relative to available funding for tuberculosis control were compared with costs of new diagnostics relative to available funding for tuberculosis [25] . Countries report the budget for their National TB Programme on an annual basis to the Global TB Programme at WHO [1] . Out of the 36 countries, 2 countries did not report financial data; therefore, results for each of the 34 individual countries are available upon request. In this article we show results for the 34 countries as a group. Methods used for this assessment have been described in further detail prior to this study [22] .
Analyses were performed using STATA/SE 13.1. 
RESULTS
Numbers of Tests and Costs
An estimated 21 million people presumed to have tuberculosis in the 36 high tuberculosis and MDR-tuberculosis-burden countries were tested using the conventional methods, with an estimated total cost of US $119 million in year 2012 ( Figure 1 , Table 3 ). Out of the 21 million people tested, 1.1 million people were tested using Xpert. Costs of using Xpert accounted for 13% of total costs of using the conventional methods. Capital investments in smear microscopy laboratories and the recurrent costs of smears accounted for the largest share of total costs using conventional diagnostics, 25% and 20%, respectively. Overall, the use of the 3 new diagnostics (RSP, BMT, and TT) would reduce diagnostic costs compared to the cost of conventional methods if the unit cost per test is US $2 or less (Figure 1 ). The cost of using the rapid sputum-based test with a unit cost of US $4 (together with equipment cost of US $500) resulted in an increase in diagnostic costs by 13% compared to the cost of using conventional methods. Diagnostic costs increased by 57% in the 36 countries when using the rapid sputum-based test with a higher unit cost per test of US $6 and equipment costs of US $1400. Using a biomarker test with a unit cost of US $4 resulted in similar diagnostic costs compared with the cost of using of conventional methods. However, using a biomarker test with a high unit cost per test of US $6 increased the diagnostic cost by 44% in the 36 countries compared to the costs of using conventional diagnostics. The triage strategy-TT followed by Xpert-reduced diagnostic costs by 31% at a unit cost per test of US $1, and by 7% at a unit cost of US $2 in the 36 countries compared with the costs of using conventional methods. At a higher unit cost of US $4, the use of a triage strategy increased diagnostic costs by 38% compared to the cost of using conventional methods. Results as described above show a common pattern among the individual 36 countries, with the exception of Russia and South Africa. In these 2 countries, the cost of using any of the new strategies with any of the three unit costs per test seemed to be less than using conventional diagnostics; the reason being that costly culture is routinely integrated into the algorithm for the diagnosis of tuberculosis. Results for the 22 high-burden countries as a group, for the 27 high MDR-tuberculosis burden countries as a group and for the group of Brazil-Russia-India-China-South-Africa (BRICS) are available in Supplement material. Results for each country are available upon request.
The total cost of diagnosing tuberculosis and MDR-tuberculosis using conventional methods is estimated at US $162 million for the year 2012 ( Figure 2 , Table 3 ). This included the cost of using liquid culture and DST for diagnosis of MDR-tuberculosis in an estimated 1.5 million tuberculosis cases. 
Affordability at a Country Level
The affordability of each alternative strategy in 34 countries as a group is illustrated in Figures 3 and 4 (Supplementary Tables 1   Figure 1 . Estimated costs of diagnosing tuberculosis using conventional methods (Conv) compared with the costs of using a rapid sputum-based test (RSP), biomarker test (BMT), and triage test followed by Xpert (TT), US$, year 2012, 36 focused countries. Capital costs (K) include only equipment. Recurrent costs (uc) include reagents, chemicals and consumables of the test. Capital costs for the conventional diagnostics include investments for equipment for smear laboratories, for laboratories for culture in liquid media and Xpert machines. and 2 illustrates results for each country). In the 34 countries, the cost of using conventional methods with the goal of reaching the Global Plan targets for tuberculosis diagnosis represented around 11% of the currently available funding for tuberculosis, with a maximum of 96% (Democratic Republic of the Congo) and a minimum of 0.2% (Russia). The cost of using a RSP was between 8% and 16% of the available funding for tuberculosis in the 34 countries. The cost of using the BMT as a proportion of the available funding for tuberculosis was between 6% and 16% for the 34 countries. Similarly, the cost of using the triage strategy-followed by Xpert-ranged between 8% and 15% of the available funding for tuberculosis for the 34 counties as a group.
For the diagnosis of tuberculosis and MDR-tuberculosis, the cost of using the conventional methods was around 14% of the available funding for tuberculosis ( Figure 4 ). For the 12 lowincome countries, it represented 16% of the available funding for tuberculosis (more details in Supplementary Tables 1 and 2 ). Costs of diagnosing tuberculosis and DR-tuberculosis using a 2-step novel diagnostic test represented between 16% and 21% of the available funding for tuberculosis in the 34 countries considered. Using one single test to diagnose tuberculosis and DRtuberculosis would take up the highest proportion of available funding compared to the other strategies, ranging between 15% and 44% for the 34 countries.
DISCUSSION
This is the first study to our knowledge to assess the costs and affordability of the new diagnostics as described in the TPPs for detection of tuberculosis and DR-tuberculosis in 36 high tuberculosis and high MDR-tuberculosis burden countries. This study provides further information on the boundaries of the unit costs that would be affordable for countries. Our results suggest that a triage strategy, with both minimal and optimal characteristics [11] , followed by a confirmatory test like Xpert, reduces the costs of diagnosing tuberculosis in all 36 countries compared to the use of conventional diagnostic methods, as well as compared to the use of a rapid sputumbased test. This analysis also supports a recent hypothetical cost-effectiveness analysis that suggested that a TT prior to Xpert implemented at the same level as Xpert (with a TT with a sensitivity equal to Xpert and a specificity of 75%) would reduce diagnostic costs even at a high unit cost of US $5 in the 3 countries sampled (Uganda, India, and South Africa) [7] . Our analysis further considers implementation of the triage strategy at the community level, which would improve coverage (it is assumed that it would reach 30% more people), compared to the use of conventional diagnostics, and still the TT would remain affordable (although increased treatment costs were not factored in).
A rapid sputum-based test with a better sensitivity compared to microscopy would increase the number of patients diagnosed and at a unit cost per test up to US $4 would result in similar or lower costs compared to the cost of using conventional diagnostics. Even the biomarker test with an expected increase in coverage of 20% would reduce diagnostic costs under optimal characteristics with a unit cost per test below US $4.
The next generation of DSTs is intended to be used at lower levels of the health-care system and has better sensitivity compared to current methods. At the costs anticipated in this article, these tests would result in similar or higher diagnostic costs compared to the cost of using conventional methods. A test that first detects tuberculosis and then identifies drug resistance in a second step at US $15 would approach the cost of the conventional strategy. Only a test that performs detection and DST in one step [Combined D-DST] with a unit cost at or below US $5 would be cheaper than conventional diagnostics. However, currently no diagnostic solution is likely to meet such a price point when detection and DST are combined.
Although our calculations are conservative, there are several factors that limit our analysis. First, the number of people with signs and symptoms of tuberculosis to be tested is based on the assumption that there are 10 suspects per 1 smear-positive tuberculosis case notified in 2012. A recent publication that collected country data on number of sputum smears tests done in 2012 [26] shows that our baseline number of suspects may be an underestimate. However, any change in size of the population requiring tests will affect all strategies largely in the same way and therefore does not affect this relative comparison of costs. Second, we did not consider the cost implications of the alternative strategies for patients and their families. In theory, the TT and BMT strategy should reduce costs to patients by facilitating access to diagnosis at the community level, but is not reflected in our current calculations. Third, labor and transport (mainly for culture samples) were not included in the unit cost of any tests. Therefore, it is possible that costs have been underestimated. Fourth, we used one single unit cost for each test in the conventional diagnostics from the WHO budgeting tool, because this tool is used at country level for budgeting. However, we acknowledge that there is great variety in the unit costs of culture and DST tests among published articles. Fifth, novel tests for DST may include a broader portfolio of drug resistance tests. Conventional diagnosis of DR-tuberculosis, however, only detects resistance against first line drugs. This potential added benefit of novel tests is not reflected in our current costs. Sixth, capital costs in the conventional strategy are based on the assumptions of the Global Plan in terms of number of laboratories required per population. We recognize that the capital investment in some countries could be higher than is anticipated by the Global Plan.
We have defined affordability by comparing the costs of diagnosis to the current levels of available funding at country level. However, current available funding entails great variability across countries. Recent analyses show that BRICS and uppermiddle income countries are increasingly able to mobilize resources for almost all their funding needs from domestic sources [27, 28] . In contrast, low-income countries rely mostly on donor funding to meet their financial needs. Donor funding accounted for 67% of total funding in low-income countries in 2011. The estimated funding gap to reach targets set in the Global Plan to Stop TB is substantial and requires much more resources to be mobilized domestically and from donors.
Costs faced by patients and their families during the diagnostic pathway for tuberculosis can represent on average up to 53% of annual household income per capita [29] . Novel diagnostics for tuberculosis that could reduce the financial burden faced by families are needed. The novel diagnostic tests modeled herein theoretically will reduce the financial burden for patients either through use closer to the patient or improved accuracy.
We greatly encourage further cost-effectiveness and transmission modeling to evaluate the implications of the new tests and to determine the most cost-effective algorithm using detailed country data.
CONCLUSIONS
New methods for diagnosing tuberculosis and DR-tuberculosis are essential to improve tuberculosis prevention, care, and control. Our results suggest that from a cost and affordability perspective, introduction of a TT (followed by Xpert) or a biomarker test (with optimal characteristics as defined in the TPP) would reduce diagnostic costs and improve coverage compared to the conventional diagnosis that relies on smear microscopy. To ensure affordability of the RSP and of the next generation of DSTs, further funding for tuberculosis at the country level is needed or the lowest unit cost for the new tests must be achieved.
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